Arcturus Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2013)

Organization Overview

First Clinical Trial
2020
NCT04416126
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Arcturus Therapeutics, Inc. | Vinbiocare Biotechnology Joint Stock Company

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: Arcturus Therapeutics (1) Acquired (1)

arct-154 (2 trials)

pyridoxine (8 trials)

Drugs in Phase 2 Trials (2)

arct-021 (4 trials)

arct-165 (1 trial)

Drugs in Phase 1 Trials (1)

arct-810 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Infections (Phase 2)

Ornithine Carbamoyltransferase Deficiency Disease (Phase 1)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 5